Abstract
Exosomes are nano-sized extracellular vesicles that have been extensively investigated for their role in cell-to-cell communication and disease progression. Owing to its inherent properties of low size, high safety profile, and excellent cellular penetrability, they are favorable candidates for many therapeutic purposes including targeted therapy, drug delivery and vaccine platform. While there is exponential rise in research exploring potential therapeutic effect of exosomes, they are still in the preliminary stage of development towards a clinical therapy. Exosome being a cell secretory product, to exploit them as scalable, cGMP-compliant manufacturing level is a major challenge at present. Here I present a strategy for the mass isolation of exosome using conditioned media of adipose derived mesenchymal stem cells. This approach is ultracentrifugation based enhanced secretion of apoptotic cell derived exosome where isolated exosomes were characterized by NTA, electron microscopy and Exoview. The purpose of this paper is to overcome the existing barrier of low exosome yield thus, enabling large-scale exosome manufacturing which may lead to rapid translation of exosome-based therapy into clinical settings.
